🧬 Silencing Risk: Lepodisiran vs Lp(a)
May 09, 2025•4 min
Listen to this episode in Metacast mobile app
Don't just listen to podcasts. Learn from them with transcripts, summaries, and chapters for every episode. Skim, search, and bookmark insights. Learn more
Episode description
🚨 New hope for high Lp(a)!
💉 Lepodisiran, a long-acting siRNA, slashed Lp(a) by 94% with just 2 shots/year.
🔬 RNA precision meets cardiac prevention.
📉 Silent killer, silenced.
#CardioTwitter #RNAtherapy #LipoproteinA
For the best experience, listen in Metacast app for iOS or Android